Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.

Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E; Atrial Arrhythmia Conversion Trial Investigators.

Circ Arrhythm Electrophysiol. 2009 Dec;2(6):652-9. doi: 10.1161/CIRCEP.109.870204.

2.

Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.

Duggan ST, Scott LJ.

Drugs. 2011 Jan 22;71(2):237-52. doi: 10.2165/10489050-000000000-00000. Review. Erratum in: Drugs. 2011 Feb 12;71(3):381.

PMID:
21275448
3.

Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.

Tsuji Y, Dobrev D.

Vasc Health Risk Manag. 2013;9:165-75. doi: 10.2147/VHRM.S43720. Epub 2013 Apr 23. Review.

4.

Vernakalant: RSD 1235, RSD-1235, RSD1235.

[No authors listed]

Drugs R D. 2007;8(4):259-65. Review.

PMID:
17596113
5.

Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.

Savelieva I, Graydon R, Camm AJ.

Europace. 2014 Feb;16(2):162-73. doi: 10.1093/europace/eut274. Epub 2013 Oct 9. Review.

PMID:
24108230
6.

Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.

Duggan ST, Scott LJ.

Drugs Aging. 2011 Jun 1;28(6):501-4. doi: 10.2165/11207060-000000000-00000. Review.

PMID:
21639409
7.

Vernakalant: A novel agent for the termination of atrial fibrillation.

Finnin M.

Am J Health Syst Pharm. 2010 Jul 15;67(14):1157-64. doi: 10.2146/ajhp080501. Review.

PMID:
20592320
8.

Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.

Guerra F, Matassini MV, Scappini L, Urbinati A, Capucci A.

Expert Rev Cardiovasc Ther. 2014 Sep;12(9):1067-75. doi: 10.1586/14779072.2014.943662. Epub 2014 Aug 5. Review.

PMID:
25096598
9.

Vernakalant in the management of atrial fibrillation.

Cheng JW.

Ann Pharmacother. 2008 Apr;42(4):533-42. doi: 10.1345/aph.1K542. Epub 2008 Mar 11. Review.

PMID:
18334607
10.

[Vernakalant for the conversion of atrial fibrillation of recent onset].

Seoane L, Baranchuk A, Conde D.

Medicina (B Aires). 2015;75(4):239-44. Review. Spanish.

11.

Vernakalant. Too dangerous in atrial fibrillation.

[No authors listed]

Prescrire Int. 2012 May;21(127):119-22. Review.

PMID:
22827000
12.

Vernakalant for the conversion of atrial fibrillation: the new kid on the block?

Conde D, Baranchuk A.

Ann Noninvasive Electrocardiol. 2014 Jul;19(4):299-302. doi: 10.1111/anec.12164. Epub 2014 Apr 16. Review.

PMID:
24738652
13.

Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.

Fedida D.

Expert Opin Investig Drugs. 2007 Apr;16(4):519-32. Review.

PMID:
17371199
14.

Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.

Howard PA.

Ann Pharmacother. 1999 Jan;33(1):38-47. Review.

PMID:
9972384
15.

Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.

Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.

Expert Opin Investig Drugs. 2008 May;17(5):805-10. doi: 10.1517/13543784.17.5.805 . Review.

PMID:
18447605
16.

Vernakalant hydrochloride to treat atrial fibrillation.

Brown RA, Lau YC, Lip GY.

Expert Opin Pharmacother. 2014 Apr;15(6):865-72. doi: 10.1517/14656566.2014.898751. Epub 2014 Mar 11. Review.

PMID:
24617913
17.

Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.

Blomström-Lundqvist C, Blomström P.

Expert Opin Drug Saf. 2012 Jul;11(4):671-9. doi: 10.1517/14740338.2012.679262. Epub 2012 May 26. Review.

PMID:
22632377
18.

Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter.

Kowey PR, VanderLugt JT, Luderer JR.

Am J Cardiol. 1996 Oct 17;78(8A):46-52. Review.

PMID:
8903276
19.

Vernakalant: pharmacology electrophysiology, safety and efficacy.

Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.

Drugs Today (Barc). 2008 May;44(5):325-9. doi: 10.1358/dot.2008.44.5.1216597. Review.

PMID:
18548135
20.

[New developments in the antiarrhythmic therapy of atrial fibrillation].

Ravens U.

Herzschrittmacherther Elektrophysiol. 2014 Mar;25(1):41-6. doi: 10.1007/s00399-014-0302-1. Epub 2014 Feb 5. Review. German.

PMID:
24496483

Supplemental Content

Support Center